Newsroom | 12447 results

Sorted by: Latest
Surgery
-

OpenEvidence and Society of Surgical Oncology Announce Strategic Partnership to Advance Surgical Cancer Care and Launch SSO Innovator Grant

MIAMI & ROSEMONT, Ill.--(BUSINESS WIRE)--Today, the Society of Surgical Oncology (SSO), a global professional society for cancer surgeons, and OpenEvidence, the most widely used medical knowledge platform, announced a strategic partnership to strengthen access to the most trusted surgical oncology evidence at the point of care while building a foundation for innovative collaborations to support surgeons and all physicians taking care of patients with cancer. Together, SSO and OpenEvidence will...
-

Augmented Reality Enters a New Phase: Michigan Surgeon Performs First U.S. Knee Replacement Using Pixee’s Knee+ NexSight Smart Glasses

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Orthopedic Specialists of Oakland County (OSOC) announced today that Dr. Safa S. Kassab has become the first surgeon in the United States to perform a total knee replacement using Pixee Medical's Knee+ NexSight augmented reality (AR) glasses — a wearable heads-up display that delivers real-time surgical guidance directly into the surgeon's field of vision inside the operating room. The milestone marks a significant advancement in surgical precision tech...
-

Middlesex Orthopedic & Spine Associates First in New England to Offer Advanced Thumb Joint Replacement for Arthritis

MIDDLESEX, Conn.--(BUSINESS WIRE)--Middlesex Orthopedic & Spine Associates first in New England to offer advanced thumb Joint replacement for arthritis....
-

Miach Orthopaedics Names Jamal Rushdy President & CEO

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Jamal Rushdy has been selected as Miach Orthopaedics' next president and CEO. He will assume the role on May 18....
-

4D EMR Debuts 4D Scribe, an AI Medical Scribe That Gives Clinicians Back 60% of Their Charting Time

LAS VEGAS--(BUSINESS WIRE)--Aesthetics software 4D EMR introduces its new 4D Scribe, an AI-powered tool designed to save plastic surgeons 60% of their charting time....
-

HistoSonics推进更多组织摧毁术应用，宣布向FDA提交肾脏肿瘤治疗申请

明尼阿波利斯--(BUSINESS WIRE)--(美国商业资讯)-- Edison®组织摧毁术系统及新型组织摧毁术治疗平台的研发企业HistoSonics今日宣布，已向美国食品药品管理局(FDA)提交De Novo申请，寻求扩大Edison®组织摧毁术系统的适用范围，纳入肾脏肿瘤破坏治疗。 这一里程碑标志着公司使命迈出重要一步：依托完全无创的技术变革实体肿瘤治疗方式，该技术利用聚焦超声以机械方式液化并破坏目标组织，降低与手术、放疗及其他常规疗法相关的多种并发症和副作用风险。 HistoSonics董事长兼首席执行官Mike Blue表示：“本次申请是组织摧毁术的适用范围从肝脏拓展至肾脏领域的重要里程碑，肾脏领域的患者和临床医生均在寻求可保留器官、保护肾单位的替代治疗方案。我们认为，组织摧毁术有潜力从根本上改变实体肿瘤的治疗方式，提供精准、无创的疗法，守护好最重要的方面——包括患者生活质量。” 本次申请由正在开展的#HOPE4KIDNEY临床试验(NCT05820087)的临床证据作为支撑。该试验为前瞻性、多中心、单臂关键性临床试验，旨在评估Edison®系统用于破坏目标肾脏肿瘤的安全...
-

HistoSonics s’engage à développer de nouvelles applications de l’histotripsie et annonce le dépôt d’une demande auprès de la FDA concernant les tumeurs rénales

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, développeur de l’Edison® Histotripsy System et d’une nouvelle plateforme thérapeutique d’histotripsie, a annoncé aujourd’hui avoir déposé une demande De Novo auprès de la Food and Drug Administration (FDA) américaine afin d’obtenir l’autorisation d’étendre l’utilisation de son Edison® Histotripsy System à la destruction des tumeurs rénales. Cette étape marque une avancée significative dans la mission de l’entreprise visant à transformer le traitement d...
-

Riassunto: HistoSonics si prepara a portare avanti altre richieste di istotripsia annunciando l'inoltro all'FDA per i tumori al rene

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, lo sviluppatore del sistema Edison® per l'istotripsia e della nuova piattaforma terapeutica per l'istotripsia, oggi ha annunciato di aver inoltrato alla Food and Drug Administration statunitense una richiesta De Novo di autorizzazione ad ampliare l'utilizzo del suo sistema Edison® per l'istotripsia per includere la distruzione dei tumori al rene. Questo traguardo segna un notevole passo avanti verso la missione di trasformare il trattamento di tumori s...
-

HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors...
-

Samenvatting: HistoSonics zet zich in voor de ontwikkeling van nieuwe toepassingen voor histotripsie en kondigt aan dat er een aanvraag bij de FDA is ingediend voor niertumoren

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, de ontwikkelaar van het Edison® Histotripsy-systeem en een innovatief platform voor histotripsy-therapie, heeft vandaag bekendgemaakt dat het een De Novo-aanvraag heeft ingediend bij de Amerikaanse Food and Drug Administration (FDA) voor toestemming om het gebruik van zijn Edison® Histotripsy-systeem uit te breiden naar de vernietiging van niertumoren. Deze mijlpaal betekent een belangrijke stap voorwaarts in de missie van het bedrijf om de behandeling...